DRAXIMAGE MDP-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DRAXIMAGE MDP-10 (DRAXIMAGE MDP-10).
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
| Metabolism | Not metabolized; excreted unchanged primarily by renal glomerular filtration. |
| Excretion | Renal: 95% within 6 hours; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection. |
| Protein binding | Weak protein binding (<5%), primarily to albumin. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid and bone. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Accumulation in bone within 1-2 hours, optimal imaging at 2-4 hours post-injection. |
| Duration of Action | Duration of imaging utility: 4-6 hours post-injection; bone uptake stable for imaging within 2-6 hours. |
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines; use caution in severe renal impairment as elimination may be delayed. |
| Liver impairment | No adjustment required; drug undergoes minimal hepatic metabolism. |
| Pediatric use | Adjusted by body weight: 9-12 MBq/kg (0.25-0.33 mCi/kg) minimum 37 MBq (1 mCi). |
| Geriatric use | No specific dose adjustment; follow adult dosing with consideration for renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DRAXIMAGE MDP-10 (DRAXIMAGE MDP-10).
| Breastfeeding | Technetium-99m medronate is excreted in breast milk. M/P ratio not established. Radioactivity may be present for up to 24 hours. Advise temporary cessation of breastfeeding for at least 24 hours post-injection; discard pumped milk during this period. |
| Teratogenic Risk | DRAXIMAGE MDP-10 contains technetium-99m medronate. The radiation dose to the fetus is minimal (estimated <0.5 mGy) with standard administered activity. No structural teratogenicity reported; however, theoretical risk of stochastic effects from ionizing radiation, especially during organogenesis (weeks 2-15). Use only if potential benefit justifies risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to medronate or any component of the formulation"]
| Precautions | ["Risk of tissue damage from extravasation; ensure proper intravenous administration","Radiopharmaceuticals may cause fetal harm; use only if benefit justifies risk in pregnancy","Use caution in patients with renal impairment as clearance may be reduced"] |
Loading safety data…
| Fetal Monitoring | Ensure pregnancy status prior to administration. Monitor for hypersensitivity reactions. No specific fetal monitoring required after diagnostic administration. |
| Fertility Effects | No evidence of adverse effects on fertility from technetium-99m medronate. Radiation exposure may theoretically impact germ cells, but standard diagnostic doses are far below thresholds for mutagenesis. |